Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Cerdelga

This page shows the latest Cerdelga news and features for those working in and with pharma, biotech and healthcare.

R&D productivity takes off

R&D productivity takes off

Among these, notable examples include PTC Therapeutics' Translarna (ataluren) - the first medicine approved for the treatment of Duchenne muscular dystrophy (DMD) - and Sanofi/Genzyme's Cerdelga (eliglustat) for Gaucher disease, a

Latest news

  • Genzyme's oral Gaucher drug cleared in Europe Genzyme's oral Gaucher drug cleared in Europe

    Genzyme's oral Gaucher drug cleared in Europe. Cerdelga now available to adults with type 1 Gaucher disease. ... In contrast, Cerdelga and Zavesca are glucosylceramide synthase inhibitors, which work by reducing the substrate for the deficient enzyme.

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    The Committee for Medicinal Products for Human Use (CHMP) backed Genzyme's Cerdelga (eliglustat) and Boehringer Ingelheim's Ofev (nintedanib) in its latest round of opinions - which are usually followed by ... Cerdelga has demonstrated it is as effective

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    The remainder of its growth portfolio are Cerdelga (eliglustat) for Gaucher disease - the only approved oral, first-line therapy for the rare genetic disease, Lemtrada (alemtuzumab) for multiple sclerosis and sarilumab,

  • FDA gives green light to Genzyme’s oral Gaucher drug FDA gives green light to Genzyme’s oral Gaucher drug

    FDA gives green light to Genzyme’ s oral Gaucher drug. Oral therapy Cerdelga is set to complement intravenous Cerezyme. ... the possibility that Cerdelga could be used alongside Cerezyme as a combination regimen.

  • Genzyme on track for eliglustat filing in 2013 Genzyme on track for eliglustat filing in 2013

    Says oral Gaucher disease drug as effective as its injectable Cerezyme

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Cerdelga (eliglustat) sold by Vertex. Acquisition 75% royalty stream. 66. Five Prime Therapeutics / BMS.

  • Pharma deals during November 2014 Pharma deals during November 2014

    In another similar deal, PDL Biopharma acquired the 75% of the University of Michigan's worldwide royalty interest in Cerdelga (eliglustat) for $66m. ... Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia